Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 415

1.

TB-IRIS pathogenesis and new strategies for intervention: Insights from related inflammatory disorders.

Cevaal PM, Bekker LG, Hermans S.

Tuberculosis (Edinb). 2019 Sep 13;118:101863. doi: 10.1016/j.tube.2019.101863. [Epub ahead of print] Review.

2.

Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa.

Gray GE, Huang Y, Grunenberg N, Laher F, Roux S, Andersen-Nissen E, De Rosa SC, Flach B, Randhawa AK, Jensen R, Swann EM, Bekker LG, Innes C, Lazarus E, Morris L, Mkhize NN, Ferrari G, Montefiori DC, Shen X, Sawant S, Yates N, Hural J, Isaacs A, Phogat S, DiazGranados CA, Lee C, Sinangil F, Michael NL, Robb ML, Kublin JG, Gilbert PB, McElrath MJ, Tomaras GD, Corey L.

Sci Transl Med. 2019 Sep 18;11(510). pii: eaax1880. doi: 10.1126/scitranslmed.aax1880.

PMID:
31534016
3.

Assessing the Impact of a Small-Group Behavioral Intervention on Sexual Behaviors Among Adolescent Girls and Young Women in Lilongwe Malawi: A Quasi-Experimental Cohort Study.

Rosenberg NE, Gichane MW, Vansia D, Phanga T, Bhushan NL, Bekker LG, Pettifor AE.

AIDS Behav. 2019 Sep 11. doi: 10.1007/s10461-019-02669-4. [Epub ahead of print]

PMID:
31512067
4.

Factors associated with knowledge of pre-exposure prophylaxis in pregnant women in Cape Town, South Africa.

DiTullio DJ, Farley E, Gomba Y, Coates TJ, Bekker LG, Myer L, Joseph Davey DL.

Int J STD AIDS. 2019 Aug 28:956462419863216. doi: 10.1177/0956462419863216. [Epub ahead of print] No abstract available.

PMID:
31462164
5.

Mobile sexual health services for adolescents: investigating the acceptability of youth-directed mobile clinic services in Cape Town, South Africa.

Smith P, Tolla T, Marcus R, Bekker LG.

BMC Health Serv Res. 2019 Aug 19;19(1):584. doi: 10.1186/s12913-019-4423-4.

6.

Community perspectives of South African adolescents' experiences seeking treatment at local HIV clinics and how such clinics may influence engagement in the HIV treatment cascade: a qualitative study.

Ritchwood TD, Ba A, Ingram L, Atujuna M, Marcus R, Ntlapo N, Oduro A, Bekker LG.

AIDS Care. 2019 Aug 11:1-6. doi: 10.1080/09540121.2019.1653442. [Epub ahead of print]

PMID:
31402674
7.

HIV pre-exposure prophylaxis for adolescent girls and young women in Africa: from efficacy trials to delivery.

Celum CL, Delany-Moretlwe S, Baeten JM, van der Straten A, Hosek S, Bukusi EA, McConnell M, Barnabas RV, Bekker LG.

J Int AIDS Soc. 2019 Jul;22 Suppl 4:e25298. doi: 10.1002/jia2.25298.

8.

Brief Report: Routine Use of Oral PrEP in a Phase 2 Rectal Microbicide Study of Tenofovir Reduced-Glycerin 1% Gel (MTN-017).

Liu AY, Norwood A, Gundacker H, Carballo-Diéguez A, Johnson S, Patterson K, Bekker LG, Chariyalertsak S, Chitwarakorn A, Gonzales P, Holtz TH, Mayer KH, Zorrilla C, Buchbinder S, Piper JM, Lama JR, Cranston RD.

J Acquir Immune Defic Syndr. 2019 Aug 15;81(5):516-520. doi: 10.1097/QAI.0000000000002066.

PMID:
31299013
9.

Prevalence and correlates of sexually transmitted infections in pregnancy in HIV-infected and- uninfected women in Cape Town, South Africa.

Joseph Davey DL, Nyemba DC, Gomba Y, Bekker LG, Taleghani S, DiTullio DJ, Shabsovich D, Gorbach PM, Coates TJ, Klausner JD, Myer L.

PLoS One. 2019 Jul 1;14(7):e0218349. doi: 10.1371/journal.pone.0218349. eCollection 2019.

10.

Low Disclosure of PrEP Nonadherence and HIV-Risk Behaviors Associated With Poor HIV PrEP Adherence in the HPTN 067/ADAPT Study.

Ojeda VD, Amico KR, Hughes JP, Wilson E, Li M, Holtz TH, Chitwarakorn A, Grant RM, Dye BJ, Bekker LG, Mannheimer S, Marzinke M, Hendrix CW.

J Acquir Immune Defic Syndr. 2019 Sep 1;82(1):34-40. doi: 10.1097/QAI.0000000000002103.

PMID:
31169769
11.

Impact of Estimated Pre-Exposure Prophylaxis (PrEP) Adherence Patterns on Bone Mineral Density in a Large PrEP Demonstration Project.

Spinelli MA, Glidden DV, Anderson PL, Gandhi M, McMahan VM, Defechereux P, Schechter M, Veloso VG, Chariyalertsak S, Guanira JV, Bekker LG, Buchbinder SP, Grant RM.

AIDS Res Hum Retroviruses. 2019 Sep;35(9):788-793. doi: 10.1089/AID.2018.0297. Epub 2019 Jun 19.

PMID:
31119944
12.

HIV control in young key populations in Africa.

Bekker LG.

Lancet Child Adolesc Health. 2019 Jul;3(7):442-444. doi: 10.1016/S2352-4642(19)30112-9. Epub 2019 May 16. No abstract available.

PMID:
31105054
13.

The HIV response and global health - Authors' reply.

Bekker LG, Beyrer C, Isbell M.

Lancet. 2019 Apr 27;393(10182):1697. doi: 10.1016/S0140-6736(19)30347-2. No abstract available.

PMID:
31034376
14.

Governance for health: the HIV response and general global health.

Bekker LG, Ratevosian J, Spencer J, Piot P, Beyrer C.

Bull World Health Organ. 2019 Mar 1;97(3):170-170A. doi: 10.2471/BLT.19.230417. No abstract available.

15.

Cardiovascular risk factors among ART-experienced people with HIV in South Africa.

Hyle EP, Bekker LG, Martey EB, Huang M, Xu A, Parker RA, Walensky RP, Middelkoop K.

J Int AIDS Soc. 2019 Apr;22(4):e25274. doi: 10.1002/jia2.25274.

16.

Modelling the potential impact of providing preexposure prophylaxis in pregnant and breastfeeding women in South Africa.

Joseph Davey DL, Bekker LG, Gomba Y, Coates T, Myer L, Johnson LF.

AIDS. 2019 Jul 1;33(8):1391-1395. doi: 10.1097/QAD.0000000000002221.

PMID:
30950882
17.

Defining characteristics of genital health in South African adolescent girls and young women at high risk for HIV infection.

Dabee S, Barnabas SL, Lennard KS, Jaumdally SZ, Gamieldien H, Balle C, Happel AU, Murugan BD, Williamson AL, Mkhize N, Dietrich J, Lewis DA, Chiodi F, Hope TJ, Shattock R, Gray G, Bekker LG, Jaspan HB, Passmore JS.

PLoS One. 2019 Apr 4;14(4):e0213975. doi: 10.1371/journal.pone.0213975. eCollection 2019.

18.

Control of the HIV-1 Load Varies by Viral Subtype in a Large Cohort of African Adults With Incident HIV-1 Infection.

Price MA, Rida W, Kilembe W, Karita E, Inambao M, Ruzagira E, Kamali A, Sanders EJ, Anzala O, Hunter E, Allen S, Edward VA, Wall KM, Tang J, Fast PE, Kaleebu P, Lakhi S, Mutua G, Bekker LG, Abu-Baker G, Tichacek A, Chetty P, Latka MH, Maenetje P, Makkan H, Kibengo F, Priddy F, Gilmour J.

J Infect Dis. 2019 Jul 2;220(3):432-441. doi: 10.1093/infdis/jiz127.

19.

Risks and Benefits of Dolutegravir- and Efavirenz-Based Strategies for South African Women With HIV of Child-Bearing Potential: A Modeling Study.

Dugdale CM, Ciaranello AL, Bekker LG, Stern ME, Myer L, Wood R, Sax PE, Abrams EJ, Freedberg KA, Walensky RP.

Ann Intern Med. 2019 May 7;170(9):614-625. doi: 10.7326/M18-3358. Epub 2019 Apr 2.

PMID:
30934067
20.

Design of an Implant for Long-Acting HIV Pre-Exposure Prophylaxis: Input from South African Health Care Providers.

Krogstad EA, Montgomery ET, Atujuna M, Minnis AM, O'Rourke S, Ahmed K, Bekker LG, van der Straten A.

AIDS Patient Care STDS. 2019 Apr;33(4):157-166. doi: 10.1089/apc.2018.0177.

PMID:
30932697
21.

Targeting and vaccine durability are key for population-level impact and cost-effectiveness of a pox-protein HIV vaccine regimen in South Africa.

Selinger C, Bershteyn A, Dimitrov DT, Adamson BJS, Revill P, Hallett TB, Phillips AN, Bekker LG, Rees H, Gray G.

Vaccine. 2019 Apr 10;37(16):2258-2267. doi: 10.1016/j.vaccine.2019.02.073. Epub 2019 Mar 16.

22.

The Invisible Product: Preferences for Sustained-Release, Long-Acting Pre-exposure Prophylaxis to HIV Among South African Youth.

Montgomery ET, Atujuna M, Krogstad E, Hartmann M, Ndwayana S, OʼRourke S, Bekker LG, van der Straten A, Minnis AM.

J Acquir Immune Defic Syndr. 2019 Apr 15;80(5):542-550. doi: 10.1097/QAI.0000000000001960.

PMID:
30865050
23.

PrEP as a Lifestyle and Investment for Adolescent Girls and Young Women in Sub-Saharan Africa.

Haberer JE, Mugo N, Baeten JM, Pyra M, Bukusi E, Bekker LG.

J Int Assoc Provid AIDS Care. 2019 Jan-Dec;18:2325958219831011. doi: 10.1177/2325958219831011.

PMID:
30776954
24.

Organisational best practices towards gender equality in science and medicine.

Coe IR, Wiley R, Bekker LG.

Lancet. 2019 Feb 9;393(10171):587-593. doi: 10.1016/S0140-6736(18)33188-X. Review.

PMID:
30739694
25.

HIV prevalence and determinants of loss-to-follow-up in adolescents and young adults with tuberculosis in Cape Town.

Mulongeni P, Hermans S, Caldwell J, Bekker LG, Wood R, Kaplan R.

PLoS One. 2019 Feb 5;14(2):e0210937. doi: 10.1371/journal.pone.0210937. eCollection 2019.

26.

Global PrEP roll-out: recommendations for programmatic success.

Rivet Amico K, Bekker LG.

Lancet HIV. 2019 Feb;6(2):e137-e140. doi: 10.1016/S2352-3018(19)30002-5. Epub 2019 Jan 16.

PMID:
30660592
27.

Factors affecting linkage to HIV care and ART initiation following referral for ART by a mobile health clinic in South Africa: evidence from a multimethod study.

Maughan-Brown B, Harrison A, Galárraga O, Kuo C, Smith P, Bekker LG, Lurie MN.

J Behav Med. 2019 Oct;42(5):883-897. doi: 10.1007/s10865-018-0005-x. Epub 2019 Jan 11.

28.

A review of the atomoRapid HIV self-testing device: an acceptable and easy alternative to facilitate HIV testing.

Smith P, Clayton J, Pike C, Bekker LG.

Expert Rev Mol Diagn. 2019 Jan;19(1):9-14. doi: 10.1080/14737159.2019.1561286. Epub 2019 Jan 10.

PMID:
30570364
29.

Sexual reproductive healthcare utilisation and HIV testing in an integrated adolescent youth centre clinic in Cape Town, South Africa.

Mendelsohn AS, Gill K, Marcus R, Robbertze D, van de Venter C, Mendel E, Mzukwa L, Bekker LG.

South Afr J HIV Med. 2018 Nov 26;19(1):826. doi: 10.4102/sajhivmed.v19i1.826. eCollection 2018.

30.

Field responsive mechanical metamaterials.

Jackson JA, Messner MC, Dudukovic NA, Smith WL, Bekker L, Moran B, Golobic AM, Pascall AJ, Duoss EB, Loh KJ, Spadaccini CM.

Sci Adv. 2018 Dec 7;4(12):eaau6419. doi: 10.1126/sciadv.aau6419. eCollection 2018 Dec.

31.

Tenofovir 1% vaginal gel for prevention of HIV-1 infection in women in South Africa (FACTS-001): a phase 3, randomised, double-blind, placebo-controlled trial.

Delany-Moretlwe S, Lombard C, Baron D, Bekker LG, Nkala B, Ahmed K, Sebe M, Brumskine W, Nchabeleng M, Palanee-Philips T, Ntshangase J, Sibiya S, Smith E, Panchia R, Myer L, Schwartz JL, Marzinke M, Morris L, Brown ER, Doncel GF, Gray G, Rees H.

Lancet Infect Dis. 2018 Nov;18(11):1241-1250. doi: 10.1016/S1473-3099(18)30428-6. Epub 2018 Oct 24.

PMID:
30507409
32.

Guidelines to support HIV-affected individuals and couples to achieve pregnancy safely: Update 2018.

Davies NECG, Ashford G, Bekker LG, Chandiwana N, Cooper D, Dyer SJ, Jankelowitz L, Mhlongo O, Mnyani CN, Mulaudzi MB, Moorhouse M, Myer L, Patel M, Pleaner M, Ramos T, Rees H, Schwartz S, Smit J, van Zyl DS.

South Afr J HIV Med. 2018 Oct 18;19(1):915. doi: 10.4102/sajhivmed.v19i1.915. eCollection 2018. No abstract available.

33.

Scaling up pre-exposure prophylaxis in sub-Saharan Africa.

Ahmed N, Pike C, Bekker LG.

Curr Opin Infect Dis. 2019 Feb;32(1):24-30. doi: 10.1097/QCO.0000000000000511.

PMID:
30461452
34.

"Why Don't You Go Into Suburbs? Why Are You Targeting Us?": Trust and Mistrust in HIV Vaccine Trials in South Africa.

Thabethe S, Slack C, Lindegger G, Wilkinson A, Wassenaar D, Kerr P, Bekker LG, Mngadi K, Newman PA.

J Empir Res Hum Res Ethics. 2018 Dec;13(5):525-536. doi: 10.1177/1556264618804740.

35.
36.

What do South African adolescents want in a sexual health service? Evidence from the South African Studies on HIV in Adolescents (SASHA) project.

Smith P, Marcus R, Bennie T, Nkala B, Nchabeleng M, Latka MH, Gray G, Wallace M, Bekker LG.

S Afr Med J. 2018 Jul 25;108(8):677-681. doi: 10.7196/SAMJ.2018.v108i8.13013.

37.

Defining adolescence: priorities from a global health perspective.

Kinghorn A, Shanaube K, Toska E, Cluver L, Bekker LG.

Lancet Child Adolesc Health. 2018 May;2(5):e10. doi: 10.1016/S2352-4642(18)30096-8. Epub 2018 Mar 23. No abstract available.

PMID:
30169271
38.

Perspectives of South African youth in the development of an implant for HIV prevention.

Krogstad EA, Atujuna M, Montgomery ET, Minnis A, Ndwayana S, Malapane T, Shapley-Quinn MK, Manenzhe K, Bekker LG, van der Straten A.

J Int AIDS Soc. 2018 Aug;21(8):e25170. doi: 10.1002/jia2.25170.

39.

Comparing Youth-Friendly Health Services to the Standard of Care Through "Girl Power-Malawi": A Quasi-Experimental Cohort Study.

Rosenberg NE, Bhushan NL, Vansia D, Phanga T, Maseko B, Nthani T, Libale C, Bamuya C, Kamtsendero L, Kachigamba A, Myers L, Tang J, Hosseinipour MC, Bekker LG, Pettifor AE.

J Acquir Immune Defic Syndr. 2018 Dec 1;79(4):458-466. doi: 10.1097/QAI.0000000000001830.

PMID:
30085953
40.

HIV and TB co-infection in the ART era: CD4 count distributions and TB case fatality in Cape Town.

Kaplan R, Hermans S, Caldwell J, Jennings K, Bekker LG, Wood R.

BMC Infect Dis. 2018 Jul 31;18(1):356. doi: 10.1186/s12879-018-3256-9.

41.

Expert consensus statement on the science of HIV in the context of criminal law.

Barré-Sinoussi F, Abdool Karim SS, Albert J, Bekker LG, Beyrer C, Cahn P, Calmy A, Grinsztejn B, Grulich A, Kamarulzaman A, Kumarasamy N, Loutfy MR, El Filali KM, Mboup S, Montaner JS, Munderi P, Pokrovsky V, Vandamme AM, Young B, Godfrey-Faussett P.

J Int AIDS Soc. 2018 Jul;21(7):e25161. doi: 10.1002/jia2.25161.

42.

Endocervical and vaginal microbiota in South African adolescents with asymptomatic Chlamydia trachomatis infection.

Balle C, Lennard K, Dabee S, Barnabas SL, Jaumdally SZ, Gasper MA, Maseko V, Mbulawa ZZA, Williamson AL, Bekker LG, Lewis DA, Passmore JS, Jaspan HB.

Sci Rep. 2018 Jul 23;8(1):11109. doi: 10.1038/s41598-018-29320-x.

43.

The global response and unmet actions for HIV and sex workers.

Shannon K, Crago AL, Baral SD, Bekker LG, Kerrigan D, Decker MR, Poteat T, Wirtz AL, Weir B, Boily MC, Butler J, Strathdee SA, Beyrer C.

Lancet. 2018 Aug 25;392(10148):698-710. doi: 10.1016/S0140-6736(18)31439-9. Epub 2018 Jul 20. Review.

44.

Advancing global health and strengthening the HIV response in the era of the Sustainable Development Goals: the International AIDS Society-Lancet Commission.

Bekker LG, Alleyne G, Baral S, Cepeda J, Daskalakis D, Dowdy D, Dybul M, Eholie S, Esom K, Garnett G, Grimsrud A, Hakim J, Havlir D, Isbell MT, Johnson L, Kamarulzaman A, Kasaie P, Kazatchkine M, Kilonzo N, Klag M, Klein M, Lewin SR, Luo C, Makofane K, Martin NK, Mayer K, Millett G, Ntusi N, Pace L, Pike C, Piot P, Pozniak A, Quinn TC, Rockstroh J, Ratevosian J, Ryan O, Sippel S, Spire B, Soucat A, Starrs A, Strathdee SA, Thomson N, Vella S, Schechter M, Vickerman P, Weir B, Beyrer C.

Lancet. 2018 Jul 28;392(10144):312-358. doi: 10.1016/S0140-6736(18)31070-5. Epub 2018 Jul 20. Review. No abstract available.

45.

The use of liver slices from the Cape vulture (Gyps coprotheres) to better understand the role of liver toxicity of non-steroidal anti-inflammatory drugs (NSAIDs) in vultures.

Adawaren EO, Mukandiwa L, Njoya EM, Bekker L, Duncan N, Naidoo V.

Environ Toxicol Pharmacol. 2018 Sep;62:147-155. doi: 10.1016/j.etap.2018.07.001. Epub 2018 Jul 4.

PMID:
30025357
46.

Inflammatory cytokine biomarkers of asymptomatic sexually transmitted infections and vaginal dysbiosis: a multicentre validation study.

Masson L, Barnabas S, Deese J, Lennard K, Dabee S, Gamieldien H, Jaumdally SZ, Williamson AL, Little F, Van Damme L, Ahmed K, Crucitti T, Abdellati S, Bekker LG, Gray G, Dietrich J, Jaspan H, Passmore JS.

Sex Transm Infect. 2019 Feb;95(1):5-12. doi: 10.1136/sextrans-2017-053506. Epub 2018 Jul 17.

PMID:
30018088
47.

Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination.

Nemes E, Geldenhuys H, Rozot V, Rutkowski KT, Ratangee F, Bilek N, Mabwe S, Makhethe L, Erasmus M, Toefy A, Mulenga H, Hanekom WA, Self SG, Bekker LG, Ryall R, Gurunathan S, DiazGranados CA, Andersen P, Kromann I, Evans T, Ellis RD, Landry B, Hokey DA, Hopkins R, Ginsberg AM, Scriba TJ, Hatherill M; C-040-404 Study Team.

N Engl J Med. 2018 Jul 12;379(2):138-149. doi: 10.1056/NEJMoa1714021.

48.

Using Observational Data to Inform HIV Policy Change for Children and Youth.

Sohn AH, Judd A, Mofenson L, Vicari M, Jerene D, Leroy V, Bekker LG, Davies MA.

J Acquir Immune Defic Syndr. 2018 Aug 15;78 Suppl 1:S22-S26. doi: 10.1097/QAI.0000000000001745.

49.

Ensuring Children and Adolescents Are Not Left Behind.

Bekker LG, Siberry GK, Hirnschall G.

J Acquir Immune Defic Syndr. 2018 Aug 15;78 Suppl 1:S1-S2. doi: 10.1097/QAI.0000000000001751. No abstract available.

50.

Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial.

Bekker LG, Moodie Z, Grunenberg N, Laher F, Tomaras GD, Cohen KW, Allen M, Malahleha M, Mngadi K, Daniels B, Innes C, Bentley C, Frahm N, Morris DE, Morris L, Mkhize NN, Montefiori DC, Sarzotti-Kelsoe M, Grant S, Yu C, Mehra VL, Pensiero MN, Phogat S, DiazGranados CA, Barnett SW, Kanesa-Thasan N, Koutsoukos M, Michael NL, Robb ML, Kublin JG, Gilbert PB, Corey L, Gray GE, McElrath MJ; HVTN 100 Protocol Team.

Lancet HIV. 2018 Jul;5(7):e366-e378. doi: 10.1016/S2352-3018(18)30071-7. Epub 2018 Jun 18.

Supplemental Content

Loading ...
Support Center